The groundbreaking success of Sildenafil undeniably revolutionized the drug landscape, but investing in companies primarily reliant on off-patent versions presents a uncertain picture. Despite early earnings were significant, the end of patents and the appearance of less expensive alternatives have eroded sales. Consequently, a thorough evaluation